Difference between revisions of "Breast cancer, HER2-positive - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...")
 
m
Line 8: Line 8:
  
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
 +
=Metastatic disease, first-line chemotherapy=
 +
'''''Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.''
 +
==AC {{#subobject:843320|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
AC: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>C</u>'''yclophosphamide
 +
===Regimen {{#subobject:2e4988|Variant=1}}===
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|Comparator
 +
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
 +
| style="background-color:#1a9851" |Phase III (C)
 +
|[[Breast_cancer,_HER2-positive#ACH|ACH]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|}
 +
''Note: patients in Slamon et al. 2001 had not previously received adjuvant (postoperative) therapy with an anthracycline.''
 +
====Chemotherapy====
 +
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
 +
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
 +
 +
'''21-day cycles'''
 +
 +
===References===
 +
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
 +
 +
==EC {{#subobject:b81844|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
EC: '''<u>E</u>'''pirubicin & '''<u>C</u>'''yclophosphamide
 +
===Regimen {{#subobject:8466d6|Variant=1}}===
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|Comparator
 +
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
 +
| style="background-color:#1a9851" |Phase III (C)
 +
|[[Breast_cancer,_HER2-positive#ECH_2|ECH]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|}
 +
====Chemotherapy====
 +
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1
 +
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
 +
 +
'''21-day cycle for up to 6 to 8 cycles'''
 +
===References===
 +
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
 +
 +
==Paclitaxel monotherapy, q3wk {{#subobject:3e5448|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:72389a|Variant=1}}===
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|Comparator
 +
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
 +
| style="background-color:#1a9851" |Phase III (C)
 +
|[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH]]
 +
| style="background-color:#fc8d59" |Seems to have inferior OS
 +
|-
 +
|}
 +
''Note: patients in EGF30001 were NOT required to be HER2-positive.''
 +
====Chemotherapy====
 +
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 +
 +
'''21-day cycles'''
 +
===References===
 +
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
  
 
[[Category:Breast cancer regimens]]
 
[[Category:Breast cancer regimens]]

Revision as of 22:45, 24 December 2019

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main HER2+ breast cancer page for current regimens.

11 regimens on this page
13 variants on this page


Metastatic disease, first-line chemotherapy

Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.

AC

back to top

AC: Adriamycin (Doxorubicin) & Cyclophosphamide

Regimen

Study Evidence Comparator Comparative Efficacy
Slamon et al. 2001 Phase III (C) ACH Seems to have inferior OS

Note: patients in Slamon et al. 2001 had not previously received adjuvant (postoperative) therapy with an anthracycline.

Chemotherapy

21-day cycles

References

  1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article PubMed

EC

back to top

EC: Epirubicin & Cyclophosphamide

Regimen

Study Evidence Comparator Comparative Efficacy
Slamon et al. 2001 Phase III (C) ECH Seems to have inferior OS

Chemotherapy

21-day cycle for up to 6 to 8 cycles

References

  1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article PubMed

Paclitaxel monotherapy, q3wk

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Slamon et al. 2001 Phase III (C) TH Seems to have inferior OS

Note: patients in EGF30001 were NOT required to be HER2-positive.

Chemotherapy

21-day cycles

References

  1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Breast_cancer,_HER2-positive_-_historical&oldid=41628"